Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL: Somavaratan in Adult Growth Hormone Deficiency
NCT02526420Phase 2Completed
- Sponsor
- Versartis, Inc.
- Start
- Jul 2015
- Primary completion
- Oct 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label trial of somavaratan in growth hormone deficiency (GHD) (3 arms), sponsored by Versartis, Inc. Primary endpoints: Safety as measured by adverse events, concomitant medications, safety labs, vital signs and physical exams at 5 months, Starting doses (proportion of subjects who achieve normalization of IGF-I SDS response) at 1 month and 1 more. Started Jul 2015; status: completed.
02
Drugs
somavaratan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02526420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02526420.